Michał Leśniak, M. Stelmach, Michał Mleko, Joanna Spaczyńska, M. Duda-Wiewiórka, M. Kabzińska-Turek, T. Popiela, K. Pityński
{"title":"PET/CT成像在复发性卵巢癌诊断及治疗方案中的应用","authors":"Michał Leśniak, M. Stelmach, Michał Mleko, Joanna Spaczyńska, M. Duda-Wiewiórka, M. Kabzińska-Turek, T. Popiela, K. Pityński","doi":"10.15557/cgo.2019.0011","DOIUrl":null,"url":null,"abstract":"follow-up period after primary treatment. No PET/CT was performed in the control group. Results: Microscopic recurrence of ovarian cancer in the region of pelvic lymph nodes was found in 29 out of 34 patients with SUV ≥2.4 and in 6 out of 51 patients with SUV <2.4. SUV ≥3.5 for para-aortic lymph nodes was associated with recurrence in this region in 24/25 cases. SUV <3.5 confirmed recurrence in only 1 out of 60 patients. Conclusions: PET/CT is characterized by high efficacy in detecting recurrence after primary treatment. PET/CT performed in the study group as part of monitoring patients after standard treatment of ovarian cancer was associated with longer survival after secondary treatment compared to women without PET/CT follow-up. SUV threshold for active neoplastic process was 3.5 for para-aortic location and 2.4 for pelvic lymph nodes.","PeriodicalId":38739,"journal":{"name":"Current Gynecologic Oncology","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PET/CT imaging in the diagnosis and treatment planning in recurrent ovarian cancer\",\"authors\":\"Michał Leśniak, M. Stelmach, Michał Mleko, Joanna Spaczyńska, M. Duda-Wiewiórka, M. Kabzińska-Turek, T. Popiela, K. Pityński\",\"doi\":\"10.15557/cgo.2019.0011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"follow-up period after primary treatment. No PET/CT was performed in the control group. Results: Microscopic recurrence of ovarian cancer in the region of pelvic lymph nodes was found in 29 out of 34 patients with SUV ≥2.4 and in 6 out of 51 patients with SUV <2.4. SUV ≥3.5 for para-aortic lymph nodes was associated with recurrence in this region in 24/25 cases. SUV <3.5 confirmed recurrence in only 1 out of 60 patients. Conclusions: PET/CT is characterized by high efficacy in detecting recurrence after primary treatment. PET/CT performed in the study group as part of monitoring patients after standard treatment of ovarian cancer was associated with longer survival after secondary treatment compared to women without PET/CT follow-up. SUV threshold for active neoplastic process was 3.5 for para-aortic location and 2.4 for pelvic lymph nodes.\",\"PeriodicalId\":38739,\"journal\":{\"name\":\"Current Gynecologic Oncology\",\"volume\":\"15 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Gynecologic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15557/cgo.2019.0011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Gynecologic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15557/cgo.2019.0011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
PET/CT imaging in the diagnosis and treatment planning in recurrent ovarian cancer
follow-up period after primary treatment. No PET/CT was performed in the control group. Results: Microscopic recurrence of ovarian cancer in the region of pelvic lymph nodes was found in 29 out of 34 patients with SUV ≥2.4 and in 6 out of 51 patients with SUV <2.4. SUV ≥3.5 for para-aortic lymph nodes was associated with recurrence in this region in 24/25 cases. SUV <3.5 confirmed recurrence in only 1 out of 60 patients. Conclusions: PET/CT is characterized by high efficacy in detecting recurrence after primary treatment. PET/CT performed in the study group as part of monitoring patients after standard treatment of ovarian cancer was associated with longer survival after secondary treatment compared to women without PET/CT follow-up. SUV threshold for active neoplastic process was 3.5 for para-aortic location and 2.4 for pelvic lymph nodes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
